References
- J.W. Coe, P.R. Brooks, M.G. Vetelino, M.C. Wirtz, E.P. Arnold, J. Huang, S.B. Sands, T.I. Davis, L.A. Lebel, C.B. Fox, et al, “Arenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation,” Journal of Medicinal Chemistry 48, no. 10 (2005): 3474–7. doi:10.1021/jm050069n.
- (a) M.R. Picciotto, M. Zoli, R. Rimondini, C. Léna, L.M. Marubio, E.M. Pich, K. Fuxe, and J.P. Changeux, “Acetylcholine Receptors Containing the β2 Subunit Are Involved in the Reinforcing Properties of Nicotine,” Nature 391, no. 6663 (1998): 173–7. doi:10.1038/34413.(b) S.S. Watkins, M.P. Epping-Jordan, G.F. Koob, and A. Markou, “Blockade of Nicotine Self-Administration with Nicotinic Antagonists in Rats,” Pharmacology, Biochemistry, and Behavior 62, no. 4 (1999): 743–51. (c) A.R. Tapper, S.L. McKinney, R. Nashmi, J. Schwarz, P. Deshpande, C. Labarca, P. Paul Whiteaker, M.J. Marks, A.C. Collins, and H.A. Lester, “Nicotine Activation of α4* Receptors: sufficient for Reward, Tolerance, and Sensitization,” Science 5 (2004): 1029–32. (d) U. Maskos, B.E. Molles, S. Pons, M. Besson, B.P. Guiard, J.-P. Guilloux, A. Evrard, P. Cazala, A. Cormier, M. Mameli-Engvall, et al., “Nicotine Reinforcement and Cognition Restored by Targeted Expression of Nicotinic Receptors,” Nature 436, no. 7047 (2005): 103–7. (e) S.R. Laviolette, and D. Van der Kooy, “The Neurobiology of Nicotine Addiction: bridging the Gap from Molecules to Behavior,” Nature Reviews Neuroscience 5 (2004): 55–65.
- A. Yarnell, “Design of an Anti-Smoking Pill,” Chemical & Engineering News Archive 83, no. 23 (2005): 36–7. doi:10.1021/cen-v083n023.p036.
- U.S. Department of Health and Human Services, Center for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office of Smoking and Health. National Youth Tobacco Survey (NYTS) Historical data and Documentation 2021-1999. https://www.cdc.gov/tobacco/data_statistics/surveys/nyts/data/index.html.
- C. Jotham Wadsworth, Niantic; Palmer Brooks, P. R, Aryl Fused Azapolycyclic Compounds, 2002. US6410550B1.
- Paul H. Mazzocchi, and Barbara C. Stahly, “Synthesis and Pharmacological Activity of 2,3,4,5-Tetrahydro-1,5-Methano-1H-3-Benzazepines,” Journal of Medicinal Chemistry 22, no. 4 (1979): 455–7. doi:10.1021/jm00190a020.
- John G. Van Alsten, Matthew L. Jorgensen, and David J. Am Ende, “Hydrogenation of a Pharmaceutical Intermediate by a Continuous Stirred Tank Reactor System,” Organic Process Research & Development 13, no. 3 (2009): 629–33. doi:10.1021/op800170r.
- Pfizer Issues a Voluntary Nationwide Recall for Twelve Lots of CHANTIX® (Varenicline) Tablets Due to N-Nitroso Varenicline Content | FDA. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/pfizer-issues-voluntary-nationwide-recall-twelve-lots-chantixr-varenicline-tablets-due-n-nitroso
- CHAMPIX (varenicline) – Lots to Be Recalled Due to Presence of Impurity N-Nitroso-Varenicline above the Pfizer Acceptable Daily Intake Limit. https://www.ema.europa.eu/en/medicines/dhpc/champix-varenicline-lots-be-recalled-due-presence-impurity-n-nitroso-varenicline-above-pfizer
- https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-pressannouncements-nitrosamine-varenicline-chantix.
- Frank R. Busch, Gregory J. Withbroe, Timothy J. Watson, Terry G. Sinay, Joel M. Hawkins, Asson G. Mustakis. US Patent No. US20080275051A1
- John G. Van Alsten, Matthew L. Jorgensen, and David J. am Ende. "Hydrogenation of a Pharmaceutical Intermediate by a Continuous Stirred Tank Reactor System," Organic Process Research & Development 13 (2009): 629–633.
- Frank R. Busch, Paul E. Concannon, Robert E. Handfield, Jason D. McKinley, Megan E. McMahon, Robert A. Singer, Timothy J. Watson, Gregory J. Withbroe, Mariano Stivanello, Lucia Leoni, et al., “Synthesis of (1-(Aminomethyl)-2,3-Dihydro1h-Inden-3-yl)Methanol: Structural Confirmation of the Main Band Impurity Found in Vareniclinew Starting Material,” Synthetic Communications 38, no. 3 (2008): 441–7. doi:10.1080/00397910701771231.
- P. Srinivas, D. Srinivasa. Reddy, B. Venkatesham, P.K. Dubey, and Javed Iqbal, “Parthasarathi Das; An Efficient Synthesis of Varenicline,” Tetrahedron Letters 51 (2010): 151–2.
- Jotham W.C. Niantic, Paige Roanne, and P.B. North Stonington. CT (US) Aryl Fused azapolycyclic Compounds. Patent No.US 6,410,550 B1.
- Health Canada Stakeholder Information Webinar Nitrosamines in Pharmaceuticals. https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/information-health-product/drugs/nitrosamine-impurities/summary-nitrosamines-stakeholder-webinar-feb-10-2021.html
- Clifford L. Coon, William G. Blucher, and Marion E. Hill, “Aromatic Nitration with Nitric Acid and Trifluoromethanesulfonic Acid,” The Journal of Organic Chemistry 38, no. 25 (1973): 4243–8. doi:10.1021/jo00964a007.
- EMA/369136/2020 Committee for Medicinal Products for Human Use (CHMP). https://www.ema.europa.eu/en/human-regulatory/post-authorisation/referral-procedures/article-53-opinions.